To address this heterogeneity, the CLDN18.2 status of a tumor should therefore be determined or re-assessed in the primary tissue and, if available and accessible, in lymph node metastasis, to ensure a correct classification and optimal consecutive patient care. This evidence concerns the gene CLDN18 and metastatic malignant neoplasm in the lymph nodes.